Minerva Neurosciences soars after co secures up to $200 million in private placement

Minerva Neurosciences

21/10/2025 13:12

** Shares of drug developer Minerva Neurosciences NERV.O rise 132.3% to $6.03 premarket

** Company says it will receive up to $200 million in gross proceeds through a private placement to fund a late-stage trial and resubmission of its experimental schizophrenia drug, roluperidone, to U.S. FDA

** The financing includes $80 million upfront and up to an additional $80 million tied to the full exercise of Tranche A warrants

** Minerva will also expand its board, adding up to three directors with schizophrenia clinical trial experience, designated by investors to support clinical operations

** The financing is led by Vivo Capital, with participation from Janus Henderson Investors, Federated Hermes Kaufmann Funds, Farallon Capital, and others

** As of last close, stock up 19.73% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))